Vaccines for the 21st century

In the last century, vaccination has been the most effective medical intervention to reduce death and morbidity caused by infectious diseases. It is believed that vaccines save at least 2–3 million lives per year worldwide. Smallpox has been eradicated and polio has almost disappeared worldwide through global vaccine campaigns. Most of the viral and bacterial infections that traditionally affected children have been drastically reduced thanks to national immunization programs in developed countries. However, many diseases are not yet preventable by vaccination, and vaccines have not been fully exploited for target populations such as elderly and pregnant women. This review focuses on the state of the art of recent clinical trials of vaccines for major unmet medical needs such as HIV, malaria, TB, and cancer. In addition, we describe the innovative technologies currently used in vaccine research and development including adjuvants, vectors, nucleic acid vaccines, and structure‐based antigen design. The hope is that thanks to these technologies, more diseases will be addressed in the 21st century by novel preventative and therapeutic vaccines.

[1]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[2]  Timothy B. Stockwell,et al.  Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics , 2013, Science Translational Medicine.

[3]  G. Aronoff,et al.  Phase IIa Study of the Immunogenicity and Safety of the Novel Staphylococcus aureus Vaccine V710 in Adults with End-Stage Renal Disease Receiving Hemodialysis , 2012, Clinical and Vaccine Immunology.

[4]  B. Guy,et al.  Evaluation of interferences between dengue vaccine serotypes in a monkey model. , 2009, The American journal of tropical medicine and hygiene.

[5]  R. Betts,et al.  Safety and Immunogenicity of a Novel Staphylococcus aureus Vaccine: Results from the First Study of the Vaccine Dose Range in Humans , 2010, Clinical and Vaccine Immunology.

[6]  R. Betts,et al.  Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. , 2013, JAMA.

[7]  Stefan H E Kaufmann,et al.  Future vaccination strategies against tuberculosis: thinking outside the box. , 2010, Immunity.

[8]  Andrea Sutherland,et al.  Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. , 2011, American journal of obstetrics and gynecology.

[9]  J. Kublin,et al.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. , 2011, The Lancet. Infectious diseases.

[10]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[11]  H. Rammensee,et al.  Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients , 2009, Journal of immunotherapy.

[12]  Franz X Heinz,et al.  Flaviviruses and flavivirus vaccines. , 2012, Vaccine.

[13]  John P. Moore,et al.  Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[14]  D. Pace MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. , 2009, Current opinion in molecular therapeutics.

[15]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[16]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[17]  S. Keam,et al.  Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix™] , 2012, BioDrugs.

[18]  Eileen M. Crimmins,et al.  Inflammatory Exposure and Historical Changes in Human Life-Spans , 2004, Science.

[19]  A. Eggermont,et al.  Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Lang,et al.  A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. , 2010, The Journal of infectious diseases.

[21]  S. Lawn,et al.  Diagnosis of extrapulmonary tuberculosis using the Xpert® MTB/RIF assay , 2012, Expert review of anti-infective therapy.

[22]  Adam Godzik,et al.  A Blueprint for HIV Vaccine Discovery. , 2012, Cell host & microbe.

[23]  H. Poulet,et al.  Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. , 2007, Vaccine.

[24]  J. Lisziewicz,et al.  Cytokine-adjuvanted HIV-DNA vaccination strategies , 2006, Springer Seminars in Immunopathology.

[25]  S. Draper,et al.  Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets , 2013, Expert review of vaccines.

[26]  U. Baxa,et al.  Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody , 2013, Science.

[27]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[28]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.

[29]  Marion Becker,et al.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.

[30]  S. Kaufmann,et al.  Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? , 2012, PLoS pathogens.

[31]  B. Polack,et al.  Live-attenuated bacteria as a cancer vaccine vector , 2013, Expert review of vaccines.

[32]  Cinque S. Soto,et al.  Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus , 2013, Science.

[33]  S. Lockhart,et al.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial , 2013, The Lancet.

[34]  B. Beutler,et al.  The interface between innate and adaptive immunity , 2004, Nature Immunology.

[35]  K. Marsh,et al.  Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial , 2011, The Lancet. Infectious diseases.

[36]  Rino Rappuoli,et al.  Reverse vaccinology. , 2000, Current opinion in microbiology.

[37]  G. Turner,et al.  Rabies: a review. , 1993, Journal of comparative pathology.

[38]  Jean C. Lee,et al.  Vaccination and passive immunisation against Staphylococcus aureus. , 2008, International journal of antimicrobial agents.

[39]  G. Poste,et al.  New Generation Vaccines , 1993, NATO ASI Series.

[40]  M. Demoitié,et al.  Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. , 2013, Vaccine.

[41]  Margaret A. Liu,et al.  Immunologic basis of vaccine vectors. , 2010, Immunity.

[42]  K. Mills,et al.  Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine , 2013, PLoS pathogens.

[43]  J. Langedijk,et al.  Structure-based design for high-hanging vaccine fruits. , 2012, Advances in immunology.

[44]  L. Wilkinson Immunity , 1891, The Lancet.

[45]  C. Mandl,et al.  Vaccines for the twenty-first century society , 2011, Nature Reviews Immunology.

[46]  V. Demicheli,et al.  Vaccines for women to prevent neonatal tetanus. , 2013, The Cochrane database of systematic reviews.

[47]  Saravudh Suvannadabba,et al.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial , 2012, The Lancet.

[48]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[49]  J. McLellan,et al.  Structure and function of respiratory syncytial virus surface glycoproteins. , 2013, Current topics in microbiology and immunology.

[50]  C. Jones,et al.  Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. , 2011, JAMA.

[51]  W. Tompson,et al.  Problems and Prospects: , 2020, Jewish Christianity.

[52]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[53]  F. Guirakhoo,et al.  Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All , 2006, Human vaccines.

[54]  H. Rammensee,et al.  Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  M. Sanford Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) , 2012, Drugs.

[56]  H. Rammensee,et al.  Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA , 2008, Journal of immunotherapy.

[57]  J. Stockman First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children , 2013 .

[58]  J. Lang,et al.  Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity , 2011, The Pediatric infectious disease journal.

[59]  Denise A. Martin,et al.  West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays , 2001, Journal of Virology.

[60]  B. Romanowski Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines , 2011, Human vaccines.

[61]  P. Pineau,et al.  La vaccination : atout majeur dans la lutte contre le cancer du foie induit par le virus de l’hépatite B , 2010 .

[62]  Shuzhao Li,et al.  Systems vaccinology: Probing humanity’s diverse immune systems with vaccines , 2014, Proceedings of the National Academy of Sciences.

[63]  Charles R. Newton,et al.  Maternal and neonatal tetanus , 2015, The Lancet.

[64]  S. Buchbinder,et al.  Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine , 2010, Current opinion in HIV and AIDS.

[65]  E. De Gregorio,et al.  Immunology of TLR-independent vaccine adjuvants. , 2009, Current opinion in immunology.

[66]  A. Calmette La vaccination preventive contre la tuberculose par le "BCG" , 1927 .

[67]  R. Schwartz,et al.  Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector , 1997, Nature Biotechnology.

[68]  C. Mandl,et al.  Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers , 2011, Proceedings of the National Academy of Sciences.

[69]  Bastian R. Angermann,et al.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.

[70]  B. Spellberg,et al.  Development of a vaccine against Staphylococcus aureus , 2011, Seminars in Immunopathology.

[71]  S. Black,et al.  Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.

[72]  S. Halstead,et al.  Dengue vaccine development: a 75% solution? , 2012, The Lancet.

[73]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[74]  M. Nussenzweig,et al.  Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.

[75]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[76]  M. Otto Novel targeted immunotherapy approaches for staphylococcal infection , 2010, Expert opinion on biological therapy.

[77]  K. Ohlsen,et al.  Immunotherapeutic strategies to combat staphylococcal infections. , 2010, International journal of medical microbiology : IJMM.

[78]  C. Rupprecht,et al.  Poxvirus-vectored vaccines for rabies--a review. , 2009, Vaccine.

[79]  R. Rappuoli,et al.  A universal vaccine for serogroup B meningococcus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[80]  S. Duggan Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®] , 2010, Drugs.

[81]  A. Shane Effectiveness of Maternal Influenza Immunization in Mothers and Infants , 2009 .

[82]  A. Bouchie GSK plows ahead with EMA malaria vaccine submission , 2013, Nature Biotechnology.

[83]  M. Demoitié,et al.  Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. , 2008, The New England journal of medicine.

[84]  R. Prymula,et al.  10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™ , 2009, Expert review of vaccines.

[85]  S. Keam,et al.  Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted Adsorbed) [Cervarix™] , 2008, Drugs.

[86]  J. Wolchok,et al.  Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. , 2011, American journal of veterinary research.

[87]  T. Monath,et al.  Yellow fever vaccination and pregnancy: a four-year prospective study. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[88]  M. Siddiqui,et al.  Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) , 2012, Drugs.

[89]  V. Demicheli,et al.  Vaccines for women for preventing neonatal tetanus. , 2015, The Cochrane database of systematic reviews.

[90]  C. Mandl,et al.  RNA: the new revolution in nucleic acid vaccines. , 2013, Seminars in immunology.

[91]  D. Weiner,et al.  Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants , 2013, Front. Immunol..

[92]  A. Hill,et al.  Viral vectors as vaccine platforms: deployment in sight. , 2011, Current opinion in immunology.

[93]  Thomas A. Smith,et al.  Simulated Impact of RTS,S/AS01 Vaccination Programs in the Context of Changing Malaria Transmission , 2012, PloS one.

[94]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[95]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[96]  R. Proctor Is there a future for a Staphylococcus aureus vaccine? , 2012, Vaccine.

[97]  Ross D. Shachter,et al.  Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. , 2009, The Journal of infectious diseases.

[98]  K. Garver,et al.  Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. , 2005, Diseases of aquatic organisms.

[99]  Brigitte Colau,et al.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.

[100]  C. Healy,et al.  Vaccines in pregnant women and research initiatives. , 2012, Clinical obstetrics and gynecology.

[101]  John P. Moore,et al.  Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[102]  J. Mascola,et al.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning , 2013, Nature Reviews Immunology.

[103]  R. Betts,et al.  The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies. , 2012, Vaccine.

[104]  Thomas Krucker,et al.  Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.

[105]  B. Walker,et al.  Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. , 2013, Vaccine.

[106]  S. Halstead,et al.  Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.

[107]  S. Kaufmann Tuberculosis vaccine development: strength lies in tenacity. , 2012, Trends in immunology.

[108]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[109]  S. Reef,et al.  Rubella vaccination of unknowingly pregnant women during mass campaigns for rubella and congenital rubella syndrome elimination, the Americas 2001-2008. , 2011, The Journal of infectious diseases.

[110]  N. Sardesai,et al.  Electroporation delivery of DNA vaccines: prospects for success. , 2011, Current opinion in immunology.

[111]  Antonio Lanzavecchia,et al.  Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.

[112]  D. Weiner,et al.  Clinical applications of DNA vaccines: current progress. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[113]  N. Sardesai,et al.  Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses , 2012, Science Translational Medicine.

[114]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[115]  Kwaku Poku Asante,et al.  Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data , 2013, The Lancet. Infectious diseases.

[116]  William R Schief,et al.  Advances in structure-based vaccine design. , 2013, Current opinion in virology.

[117]  J. Venter,et al.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.

[118]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[119]  K. Jansen,et al.  Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects". , 2013, Vaccine.